Why is "In silico" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-04-03 17:07:29
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
This topic is not currently in the ranking.
Wikipedia Overview
In biology and other experimental sciences, an in silico experiment is one performed on a computer or via computer simulation software. The phrase is pseudo-Latin for 'in silicon', referring to silicon in computer chips. It was coined in 1987 as an allusion to the Latin phrases in vivo, in vitro, and in situ, which are commonly used in biology. The latter phrases refer, respectively, to experiments done in living organisms, outside living organisms, and where they are found in nature.
Read more on Wikipedia →Related Topics
- In silico (disambiguation)
- Virtual screening
- Artificial gene synthesis
- Artificial life
- Bacillus subtilis
- Belt transect
- Bibcode (identifier)
- Biology
- Bioprocess
- COVID-19
Trending Topic Today
Search Interest Perspective
-
Lilly’s AI commitment expands through deal with Insilico - BioPharma Dive
-
Insilico Medicine CEO on how best to use AI in drug development - statnews.com
-
Eli Lilly, InSilico Strike AI Drug Discovery Deal - WSJ
-
Insilico Medicine signs $2.75B AI drug discovery deal with Eli Lilly - mobihealthnews.com
-
Lilly Doubles Down on Insilico’s AI Medicines, Bets Up to $2.75B - BioSpace
-
Eli Lilly extends partnership with Insilico Medicine for AI-powered drug discovery - Reuters
-
Lilly Grows AI Footprint with Up-to-$2.75B Insilico Collaboration - Genetic Engineering and Biotechnology News
-
Lilly further embraces Insilico’s AI tech, inking R&D collab worth up to $2.75B - Fierce Biotech
-
Lilly inks $2.75B licensing, AI discovery deal with Insilico - FirstWord Pharma
-
Lilly, Insilico Ink Deal on AI Drugs Worth Up to $2.75 Billion - Bloomberg.com
-
Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market - CNBC
-
Lilly, Insilico ink deal on AI drugs worth up to $2.75 billion - MSN
-
Eli Lilly expands AI drug push with multibillion-dollar Insilico deal (LLY:NYSE) - Seeking Alpha
-
Lilly puts up to $2.75bn into Insilico alliance - pharmaphorum
-
Lilly taps Insilico AI in $2.75B deal to expand pipeline options - BioWorld MedTech
-
Insilico Medicine and Eli Lilly Form $2.75B AI Drug Discovery Collaboration - HIT Consultant
-
Eli Lilly Is Diving Deeper Into AI Drug Discovery With Expanded Insilico Partnership - Investopedia
-
Eli Lilly expands Insilico pact with $2.75B AI drug discovery deal - techtarget.com
-
AI drug developer Insilico Medicine and Lilly ink commercialization deal worth up to $2.75 billion - statnews.com
-
Insilico Medicine secures $2.75 billion drug collaboration with Eli Lilly - Reuters
-
Eli Lilly signs $2.75 billion drug discovery deal with InSilico - Investing.com
-
Insilico Medicine inks global R&D collaboration with Lilly - The Pharma Letter
-
Eli Lilly and Insilico sign an AI drug discovery deal, paying $115M upfront - Endpoints News
-
Insilico Medicine signs AI drug development deal with Eli Lilly - South China Morning Post
-
Eli Lilly Bets $2.75B on AI Drug Discovery in Insilico Deal - The Tech Buzz
-
Insilico and ASKA partner to advance AI-driven gynecological drug discovery - News-Medical
-
Insilico and Qilu partner to create generative AI cardiometabolic drugs - Drug Target Review
-
Insilico Medicine announces inclusion in Hang Seng Index and Stock Connect program - EurekAlert!
-
In silico docking yields small molecule negative allosteric modulators targeting the core of Frizzled 7 - Nature
-
Insilico Medicine to Announce 2025 Financial Results on March 30, 2026 - Yahoo Finance
-
Eli Lilly to sign $2 billion deal for AI drug development with Hong Kong's Insilico Medicine: Report - The Economic Times
-
Insilico Medicine Lists on Hong Kong Stock Exchange, Showing AI Drug Discovery Momentum with 2025's Largest Hong Kong Biotech IPO - PR Newswire
-
No Pain, No Gain: Insilico ‘Gym’ Gets AI Models Into Shape - Genetic Engineering and Biotechnology News
-
Insilico Medicine Announces Global R&D Collaboration with Lilly - Lelezard
-
Insilico secures $888million Servier partnership for AI oncology - Drug Target Review
-
Large-scale single-cell analysis and in silico perturbation reveal dynamic evolution of HCC: from initiation to therapeutic targeting - Nature
-
Insilico Medicine Enters $120 Million Drug Development Collaboration with Qilu Pharmaceuticals to Advance Cardiometabolic Therapies - Pharmaceutical Executive
-
Insilico agrees on $66M deal to split rights for preclinical NLRP3 inhibitor with new Chinese biotech - Fierce Biotech
-
A Look At InSilico Medicine Cayman TopCo (SEHK:3696) Valuation After Recent Share Price Pullback - Yahoo Finance
-
In-silico studies, synthesis, and pharmacological screening of novel multitarget diphenylpyrazole scaffold as EGFR/BRAF and cyclooxygenase-2 inhibitors - Nature
-
In silico functional, structural, and pathogenicity assessment of single nucleotide polymorphisms in the human SOX9 gene - Nature
-
US pharma giant Eli Lilly, Insilico Medicine secure deal worth $2.75 billion to bring AI-developed drugs to market - Mint
-
Insilico Medicine receives USD 5 million milestone payment from Menarini Group following First-in-Human (FIH) achievement for MEN2501 - EurekAlert!
-
Agentic AI and the rise of in silico team science in biomedical research - Nature
-
AI drug designer Insilico Medicine aims to generate nearly $300M in Hong Kong IPO - Fierce Biotech
-
Lilly Expands AI Ties to Insilico, from Customer to Drug Discovery Partner - Genetic Engineering and Biotechnology News
-
In-silico identification of novel Cis-aconitate decarboxylase inhibitors as potential anti-inflammatory agents using molecular docking and dynamics | Scientific Reports - Nature
-
Carafe enables high quality in silico spectral library generation for data-independent acquisition proteomics - Nature
-
Insilico signs US$888 million AI drug-development deal days after Hong Kong IPO - Yahoo Finance
-
Evaluating MINFLUX experimental performance in silico - Nature
-
Insilico and Servier Strike Up to 888 Million Dollar AI Oncology Drug Discovery Deal - Oncodaily
-
Insilico Medicine and MSK collaborate to discover new drug targets for gastroesophageal malignancies - News-Medical
-
Insilico Medicine and Qilu Pharmaceutical partner to develop AI-designed cardiometabolic drugs - News-Medical
-
Lilly continues AI push, inking $100M-plus research pact with Insilico - Fierce Biotech
-
Assessing InSilico Medicine Cayman TopCo’s Valuation After A 60% 30 Day Share Price Surge - Yahoo Finance
-
In silico biological discovery with large perturbation models - Nature
-
In silico design of natural-based structures as drug candidates to inhibit ROS1 protein - Nature
-
Integrating in-silico and experimental validation approaches to unveil the therapeutic mechanism of naringenin against breast cancer - Nature
-
AI Drug Discovery Unicorn Insilico Medicine Jumps In Hong Kong Trading Debut - Forbes
-
Eli Lilly Expands Insilico AI Drug Discovery Deal to $2.75 Billion - AIM Media House
-
Insilico Medicine Receives IND Approval from FDA for ISM8969, an AI-empowered Potential Best-in-class NLRP3 Inhibitor - Yahoo Finance
-
Rational engineering of allosteric protein switches by in silico prediction of domain insertion sites - Nature
-
Antibacterial potential and in silico analysis of inflorescence-derived essential oils from three Eucalyptus species - Nature
-
Rx Rundown: Insilico Medicine, Sanofi, Eli Lilly and more - Medical Marketing and Media
-
In silico-driven identification of potent CDK9 inhibitors through bioisosteric replacement and multi-stage virtual screening - Nature
-
Social Science Moves In Silico - Stanford HAI
-
In-silico screening of small compounds against Lassa fever haemorrhagic virus nucleoprotein | Scientific Reports - Nature
-
In silico study of structure-based screening of inhibitors to block PrPC conversion and amyloid aggregation - Frontiers
-
Unlocking Information for in silico Affinity Maturation - evotec.com
-
In silico characterization, physiochemical analysis, and antifungal evaluation of the Zea mays PR-1 protein - Nature
-
Structure based in silico screening of natural Vitamin D analogs for targeted and safer treatment of resistant multiple sclerosis - Nature
-
“In silico analysis of human TLR3 missense single nucleotide polymorphisms and their potential association with cancer” - Nature
-
In Silico exploration of Karanjin for anti-obesity potential through ADMET profiling, network pharmacology, molecular docking, and molecular dynamics simulations - Nature
-
In Silico discovery of novel androgen receptor inhibitors for prostate cancer therapy using virtual screening, molecular docking, and molecular dynamics simulations - Nature
-
In silico and in vitro evaluation of drug-like properties and anticancer potential of novel 5-fluorouracil derivatives - Nature
-
In silico discovery of representational relationships across visual cortex - Nature
-
Insilico Eyes Q4 Start for Late-Stage Trials of IPF Candidate - Genetic Engineering and Biotechnology News
-
In silico approaches unveil the mechanism of action of Eclipta prostrata against acute myeloid leukemia - Nature
-
Cartilage mechanical responses during gait as in silico biomarkers for medial knee OA progression - Nature
-
Deloitte China assists listing of InSilico Medicine on SEHK - Deloitte
-
In-vitro and in-silico study to assess anti breast cancer potential of N-tosyl-indole based hydrazones - Nature
-
AI drug startup Insilico Medicine launches an AI ‘gym’ to help models like GPT and Qwen be good at science - Fortune
-
Art in Silico Gallery 2025 - Michigan Technological University
-
In-silico 3D molecular editing through physics-informed and preference-aligned generative foundation models - Nature
-
In silico exploration of anticancer plant phytochemicals for EGFR-targeted lung cancer therapy - Nature
-
A deep generative model for deciphering cellular dynamics and in silico drug discovery in complex diseases - Nature
-
Epitope mapping strategies for immunogenicity mitigation in streptokinase therapeutics: an in-silico study - Nature
-
Insilico Medicine begins clinical trial for AI-designed cancer drug ISM3412 - News-Medical
-
In silico and in vitro antibacterial evaluation of eight Anatolian Salvia species with chemical profiling by LC-HRMS - Nature
-
Insilico Medicine and UAE University achieve collaboration to foster local talent and academic innovation - EurekAlert!
-
In silico development of a multi-epitope vaccine for Pseudomonas aeruginosa - News-Medical
-
In Silico tool for predicting, designing and scanning IL-2 inducing peptides | Scientific Reports - Nature
-
Integrative in Silico and in vitro validation suggest LINC00963 and SNHG15 as candidate biomarkers for coronary artery disease - Nature
-
An in silico to in vivo approach identifies retinoid-X receptor activating tert-butylphenols used in food contact materials - Nature
-
In-silico analysis of potential phytochemicals targeting mitogen activating protein kinase-14 (MAPK14) gene in colorectal cancer - Nature
-
Capgemini and Insilico Medicine: Partnering to accelerate AI-powered drug discovery - Capgemini
-
Insilico hopes third time's a charm for planned Hong Kong IPO - FirstWord Pharma
-
Editorial: Multiscale cancer modeling, in silico oncology and digital (virtual) twins in the cancer domain - Frontiers
-
In Silico Research Is Rewriting the Rules of Drug Development: Is It the End of Human Trials? - Cureus
-
In vitro and in silico study and pharmacokinetic analysis of the acaricidal effectiveness of Cersium arvense extract against Rhipicephalus microplus - Nature
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.